Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide developed by Vladimir Khavinson’s bioregulatory peptide research program in St. Petersburg, Russia. It is classified as a liver bioregulator and has been studied in vitro for its effects on chromatin structure and gene expression. Research remains almost entirely preclinical and published primarily in Russian-language journals.

📖 Read the full Livagen research overview →

Evidence Tier: Tier 4 — Preclinical Only · Peptidings Verdict: Eyes Open